Keywords 3-in-1 T cells super circular tumor-infiltrating lymphocytes (ScTILs) PD-1 positive T cell selection TILs like cells enhance receptor biliary tract cancer therapy CAR for expansion of T cells checkpoint inhibition CAR-T for solid tumors T cell expansion in vivo Introduction Chimeric antigen receptor (CAR) T’s clinical success in hematological malignancies has reversed the view of cancer as incurable. Buoyed by this, cell therapy was expected to breakthrough in solid tumors.
